Richmond, BC – Viva Pharmaceutical announced that it has successfully completed its inspection by the U.S. Food and Drug Administration (USFDA), which took place from October 21 to October 25, 2024. This inspection is a critical component of the regulatory process, ensuring that pharmaceutical manufacturers adhere to stringent safety and quality standards.
During the five-day inspection, USFDA official evaluated Viva’s manufacturing processes, quality control measures, and compliance with Current Good Manufacturing Practices (cGMP). The company reported that the inspection went smoothly, reflecting its commitment to maintaining high standards in drug production.
Viva Pharmaceutical’s CEO expressed pride in the team’s dedication and hard work, stating, “This successful inspection underscores our commitment to delivering safe and effective products to our customers. We are dedicated to continuous improvement and compliance with all regulatory requirements.”
The completion of this inspection positions Viva Pharmaceutical favorably as it continues to expand its product offerings in the competitive market. The company looks forward to leveraging this positive outcome to enhance its reputation and foster trust among healthcare providers and patients alike.